Quick Answer
Artiva Biotherapeutics, Inc. reported R&D Expense of $69.54 million for fiscal year 2025.
Artiva Biotherapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $69.54M | +38.2% |
| 2024 | $50.33M | +0.2% |
| 2023 | $50.25M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.63M | +30.4% | -1.3% |
| June 30, 2025 | $17.86M | +44.8% | +4.7% |
| March 31, 2025 | $17.05M | +52.9% | +26.1% |
| September 30, 2024 | $13.52M | +3.5% | +9.7% |
| June 30, 2024 | $12.33M | +9.5% | +10.6% |
| March 31, 2024 | $11.16M | — | -14.6% |
| September 30, 2023 | $13.06M | — | +16.0% |
| June 30, 2023 | $11.26M | — | — |
- Artiva Biotherapeutics, Inc. showed an increase of +38.2% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Artiva Biotherapeutics, Inc.’s r&d expense has grown by 38.4% (from $50.25 million to $69.54 million).
- The most recent figure is from Artiva Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: